Communications Medicine (Jun 2024)

Mendelian randomization reveals interactions of the blood proteome and immunome in mitral valve prolapse

  • Louis-Hippolyte Minvielle Moncla,
  • Mewen Briend,
  • Mame Sokhna Sylla,
  • Samuel Mathieu,
  • Anne Rufiange,
  • Yohan Bossé,
  • Patrick Mathieu

DOI
https://doi.org/10.1038/s43856-024-00530-x
Journal volume & issue
Vol. 4, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Background Mitral valve prolapse (MVP) is a common heart disorder characterized by an excessive production of proteoglycans and extracellular matrix in mitral valve leaflets. Large-scale genome-wide association study (GWAS) underlined that MVP is heritable. The molecular underpinnings of the disease remain largely unknown. Methods We interrogated cross-modality data totaling more than 500,000 subjects including GWAS, 4809 molecules of the blood proteome, and genome-wide expression of mitral valves to identify candidate drivers of MVP. Data were investigated through Mendelian randomization, network analysis, ligand-receptor inference and digital cell quantification. Results In this study, Mendelian randomization identify that 33 blood proteins, enriched in networks for immunity, are associated with the risk of MVP. MVP- associated blood proteins are enriched in ligands for which their cognate receptors are differentially expressed in mitral valve leaflets during MVP and enriched in cardiac endothelial cells and macrophages. MVP-associated blood proteins are involved in the renewal-polarization of macrophages and regulation of adaptive immune response. Cytokine activity profiling and digital cell quantification show in MVP a shift toward cytokine signature promoting M2 macrophage polarization. Assessment of druggability identify CSF1R, CX3CR1, CCR6, IL33, MMP8, ENPEP and angiotensin receptors as actionable targets in MVP. Conclusions Hence, integrative analysis identifies networks of candidate molecules and cells involved in immune control and remodeling of the extracellular matrix, which drive the risk of MVP.